Fixed Income - Credit spreads across various industries have slightly compressed, with some industries experiencing significant widening [2][6] - The overall credit bond transaction volume increased by 458 billion yuan week-on-week, with a notable rise in the turnover rate [6][7] - The recommendation is to focus on liquid 3-5 year industrial bonds and high-yield municipal bonds with yields above 2% [6][12] Financial Data - In May, new loans amounted to 620 billion yuan, and social financing reached 2.29 trillion yuan, indicating weak credit demand [9][11] - M2 growth was stable at 7.9% year-on-year, while M1 growth rebounded to 2.3% [10][11] - The expectation is for a slight increase in new loans and significant growth in government bond financing, with social financing growth projected to be around 8.3% by year-end [11][12] Pharmaceutical Industry - The pharmaceutical index rose by 1.40%, with significant developments in Alzheimer's disease treatment, including a strategic partnership between Shiyao Group and AstraZeneca worth 5.33 billion USD [13][15] - The market potential for innovative oral drugs for Alzheimer's is promising, with a focus on companies like Tonghua Jinma [15][16] - Recommendations include companies with strong innovation capabilities and those positioned for international expansion, such as Heng Rui Medicine and Kintor Pharmaceutical [16][17] Metals and New Materials - Copper prices are expected to remain volatile, with domestic copper inventory decreasing and downstream demand slightly declining [19][20] - Aluminum prices are supported by ongoing inventory depletion, with current prices around 20,400 yuan per ton [21][22] - Lithium prices are under pressure, with a focus on potential production cuts in the mining sector [22][23] Public Utilities and Environmental Protection - The energy supply is transitioning from tight to balanced, with coal power generation expected to decline due to increased renewable energy installations [24][25] - The hydrogen energy sector is moving towards maturity, with pilot projects being initiated to enhance economic viability [27][28] - Recommendations include companies involved in traditional power generation and emerging renewable energy technologies [26][27] North Exchange - The North Exchange has accepted 25 IPO applications, with a focus on the upcoming IPO of Guangxin Technology [30][31] - The market is experiencing a downward trend, with a weekly decline of 3.11% in the North Exchange 50 index [31][32] - The overall outlook remains optimistic, with a focus on stable growth companies and sectors with high dividend yields [31][32]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][54]. Core Viewpoints - The report highlights that the AD (Alzheimer's Disease) treatment sector is expected to see significant advancements, with a recommendation to focus on companies like Tonghua Jinma and Dongcheng Pharmaceutical [3][9]. - The report emphasizes the importance of innovation, international expansion, and the aging population as key themes driving the industry forward [22][43]. - The pharmaceutical index has shown a positive performance, with a 1.40% increase from June 9 to June 13, outperforming the CSI 300 index by 1.66% [5][22]. Summary by Sections 1. AD Treatment Developments - The report notes that Alzheimer's Disease (AD) is a major global health challenge, with 51.62 million cases worldwide in 2019, including 13.14 million in China [9][10]. - The innovative oral drug, Succinyl-8-hydroxy-aminoguanidine, developed by Tonghua Jinma, has shown promising results in clinical trials and is expected to be a significant player in the AD treatment market [5][21]. 2. Industry Perspectives - The report indicates that the pharmaceutical sector is transitioning from traditional growth drivers to innovative solutions, with a focus on domestic innovation and international market expansion [22][43]. - The aging population is driving demand for chronic disease treatments, and the report suggests that the healthcare payment system is evolving to support this growth [41][43]. 3. Market Performance - The report provides a detailed analysis of stock performance, noting that 218 stocks increased in value while 263 decreased during the reporting period [5][22]. - Specific stocks such as Yiming Pharmaceutical and Sai Sheng Pharmaceutical have shown significant gains, while others like Renmin Tongtai have experienced notable declines [25][26]. 4. Investment Recommendations - The report recommends focusing on innovative pharmaceutical companies and those with strong international expansion capabilities, such as Heng Rui Pharmaceutical and Keren Pharmaceutical [43][44]. - It also highlights the importance of investing in sectors related to aging and outpatient consumption, suggesting companies like Kunming Pharmaceutical and Yuyue Medical [44].